Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2021-07-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
上海市锦天城律师事务所关于公司2019年限制性股票激励计划回购价格调整的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the adjustment of the repurchase price for a 2019 restricted stock incentive plan of a company. It contains detailed legal analysis, references to company board and shareholder meetings, and compliance with relevant laws and regulations. It does not contain financial statements, earnings data, or management discussion of financial results. It is not an announcement of a report but a standalone legal opinion document related to a specific corporate action (stock incentive plan price adjustment). This type of document does not fit into financial reports, earnings releases, or management reports. It is best classified under Regulatory Filings (RNS) as a legal proceeding or compliance-related filing that does not fit other categories.
2021-07-25 Chinese
中信证券股份有限公司关于公司2021年半年度募集资金存放与使用情况的专项核查报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "专项核查报告" (special inspection report) by 中信证券股份有限公司 regarding the 2021 half-year fundraising funds deposit and usage status of 厦门艾德生物医药科技股份有限公司. It details the actual fundraising amount, usage, management, and changes in investment projects related to the fundraising. It includes detailed financial figures and tables about the use of funds, project progress, and changes in investment projects. The document is a comprehensive report on the use and management of fundraising proceeds for a half-year period (2021 semi-annual). It is not an announcement of a report, nor a certification letter, but a substantive financial and operational report on fundraising usage. This fits the category of an Interim / Quarterly Report (IR), as it covers a period shorter than a full fiscal year and contains substantive financial data and analysis about fundraising usage and project progress. H1 2021
2021-07-25 Chinese
关于选举产生第三届监事会职工代表监事的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election of a new employee representative supervisor to the company's third supervisory board. It details the election process, the individual's background, and compliance with relevant laws and company articles. There is no financial data, no mention of annual or quarterly reports, no audit information, no voting results from a general meeting, and no other financial or regulatory filings. The content focuses on board/management information, specifically about the supervisory board composition and personnel changes. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or certification, so it is not RPA or RNS.
2021-07-25 Chinese
关于监事会换届选举的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election of new supervisors to the company's supervisory board, including candidate information and procedural details. It does not contain financial statements, audit information, or other report types. It specifically relates to changes in the company's supervisory board members, which falls under Board/Management Information. The document length is short and focused on management changes, not a report or announcement of a report publication.
2021-07-25 Chinese
2021年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2021年半年度报告摘要" which translates to "2021 Half-Year Report Summary." It contains detailed financial data such as revenue, net profit, earnings per share, total assets, and shareholder information for the half-year period. The document is about 3124 characters long, which is relatively short but contains substantive financial data and analysis for a period shorter than a full fiscal year. It is not merely an announcement or a certification but includes actual financial figures and business overview for the half-year period. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-07-25 Chinese
独立董事候选人声明（王恩华）
Board/Management Information Classification · 95% confidence The document is a formal declaration by an independent director candidate of a company, detailing compliance with various legal and regulatory requirements for serving as an independent director. It includes statements about qualifications, independence, and adherence to relevant laws and regulations. There is no financial data, no discussion of company performance, no voting results, no meeting materials, and no mention of report publication. The content is focused on board/management information, specifically about the appointment or candidacy of an independent director. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is moderate and contains detailed statements, not a brief announcement or certification only, so it is not Regulatory Filings (RNS).
2021-07-25 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.